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ABSTRACT
Background Pneumococcal conjugate vaccine (PCV) and 
rotavirus vaccine (RV) are key tools for reducing common 
causes of infant mortality. However, measurement of 
population- level mortality impact is lacking from sub- 
Saharan Africa. We evaluated mortality impact and vaccine 
effectiveness (VE) of PCV13 introduced in November 2011, 
with subsequent RV1 roll- out in October 2012, in Malawi.
Methods We conducted two independent community- 
based birth cohort studies. Study 1, in northern Malawi 
(40000population), evaluated population impact using 
change- point analysis and negative- binomial regression of 
non- traumatic 14–51- week infant mortality preintroduction 
(1 January 2004 to 31 September 2011) and postintroduction 
(1 October 2011 to 1 July 2019), and against three- dose 
coverage. Study 2, in central Malawi (465 000 population), 
was recruited from 24 November 2011 to 1 June 2015. In 
the absence of preintroduction data, individual three- dose 
versus zero- dose VE was estimated using individual- level Cox 
survival models. In both cohorts, infants were followed with 
household visits to ascertain vaccination, socioeconomic and 
survival status. Verbal autopsies were conducted for deaths.
Results Study 1 included 20 291 live births and 216 infant 
deaths. Mortality decreased by 28.6% (95% CI: 15.3 to 39.8) 
post- PCV13 introduction. A change point was identified 
in November 2012. Study 2 registered 50 731 live births, 
with 454 deaths. Infant mortality decreased from 17 to 
10/1000 live births during the study period. Adjusted VE was 
44.6% overall (95% CI: 23.0 to 59.1) and 48.3% (95% CI: 
−5.9 to 74.1) against combined acute respiratory infection, 
meningitis and sepsis- associated mortality.
Conclusion These data provide population- level evidence 
of infant mortality reduction following sequential PCV13 
and RV1 introduction into an established immunisation 
programme in Malawi. These data support increasing 
coverage of vaccine programmes in high- burden settings.
INTRODUCTION
Pneumonia remains the leading cause of 
infectious mortality in children under 5 
Key questions
What is already known?
 ► Several studies have shown post- pneumococcal 
conjugate vaccine (PCV) introduction reductions in 
pneumonia cases and hospitalisation in sub- Saharan 
Africa, and diarrhoea- specific mortality reductions 
have been attributed to rotavirus vaccine (RV).
 ► Two studies from South America have reported on 
PCV effectiveness against mortality, and a retrospec-
tive time series analysis from Morocco reported a 
30% reduction in acute respiratory infant deaths fol-
lowing PCV introduction. Other estimates of mortal-
ity effectiveness and cost- effectiveness have been 
modelled.
 ► As yet, no studies have reported prospective empiri-
cally observed PCV effectiveness and impact against 
population- level mortality in sub- Saharan Africa, and 
none have accounted for RV introduction.
What are the new findings?
 ► We report on the effectiveness and impact of 
13- valent PCV, with subsequent RV introduction, on 
population infant mortality in Malawi.
 ► We demonstrate significant reductions in all non- 
traumatic infant mortality among three- dose age- 
eligible infants following PCV13 introduction in 
Malawi, in two different locations.
 ► The reductions in mortality were associated with 
vaccine coverage. However, we were unable to fully 
disentangle the additional role of subsequent mon-
ovalent RV into the routine extended programme of 
immunisation (EPI) schedule.
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years old globally. Pneumococcal pneumonia, alongside 
meningitis and bacteraemia caused an estimated 500 
000 annual deaths in 2000, prior to widespread pneumo-
coccal conjugate vaccine (PCV) introduction, with the 
majority occurring in sub- Saharan Africa.1 2 By 2015 this 
estimate had halved with approximately 300 000 paedi-
atric pneumococcal deaths.3 Rotavirus is the leading 
cause of severe diarrhoea and a significant contributor 
to infant mortality in Africa.4 PCV and rotavirus vaccines 
(RVs) were included in the WHO extended programme 
of immunisation (EPI) recommendations for routine 
vaccination following trial evidence that they prevent life- 
threatening infections.5–7
Reductions in pneumococcal morbidity and mortality 
following PCV introduction have been reported for 
high- income settings,8–10 alongside evidence of cost- 
effectiveness.11 12 Nicaragua, the first lower- middle income 
country to introduce PCV13 in 2010, demonstrated a 33% 
reduction in hospitalised pneumonia and inpatient case- 
fatality.13 Subsequent studies of PCV10 and PCV13 imple-
mentation from Peru, Brazil and Morocco have confirmed 
infant pneumonia mortality reductions, although with 
varied levels of impact (12% to 35%).14–16 Additionally, a 
modelled study from South Africa estimated a reduction of 
61 pneumococcal- related child deaths per 100 000 child- 
years following PCV13 introduction.17
South Africa was the first African country to routinely 
introduce monovalent RV (RV1) in 2009, observing a 
57% vaccine effectiveness (VE) against rotavirus hospital-
isation, similar to the 64% VE reported from Malawi.18 19 
Effectiveness against mortality has been estimated from 
middle- income settings,20–22 and Malawi has reported a 
34% VE against vaccine age- eligible infant diarrhoeal 
mortality.23 However, population- level mortality impact 
of routine PCV (including 13- valent PCV (PCV13)) and 
sequential RV introduction in sub- Saharan Africa are yet 
to be reported.
Malawi, a low- income sub- Saharan African country, intro-
duced PCV13 (Prevenar 13) in November 2011 into a 
PCV- naive population, using a 6, 10 and 14- week schedule 
and initial year- long three- dose catch- up for infants aged 
<12 months at introduction. RV1 (Rotarix) with a 6 and 
10- week schedule, was introduced with no catch- up in 
October 2012. We aimed to prospectively evaluate popu-
lation impact and effectiveness of PCV13, in the context of 
subsequent RV1 roll- out and on- going public health initia-
tives targeting child health, on non- traumatic mortality in 
vaccine age- eligible infants in Malawi.
METHODS
We conducted two prospective population birth cohort 
studies in the Northern (Study 1) and Central (Study 
2) regions of Malawi (online supplementary eFigure 
1).24 Study 1 investigated PCV13 impact, defined as the 
population- level reduction in infant mortality; Study 
2 investigated both impact and effectiveness, with VE 
defined as the individual risk ratio in vaccinated versus 
unvaccinated infants.25
Study 1
Study 1 was conducted at the Karonga Health and Demo-
graphic Surveillance Site (KHDSS). KHDSS was established 
in 2002, currently covering a population of 40 000 people 
in 41 villages, with one rural government hospital and four 
health centres.26 Demographic data are included from 1 
January 2004 to 1 July 2019, and vaccine coverage data 
are complete up to the 1 July 2017. PCV13 was introduced 
on 12 November 2011, therefore all children born from 
1 October 2011 onwards were 6 weeks old at introduction 
and eligible to receive dose- one. This study provides a pre–
post impact evaluation of PCV13 introduction.
Data collection and cleaning
Births and deaths were recorded monthly by 230 
community- based volunteers. Vaccine and socioeco-
nomic status were collected for each household on an 
annual basis, using a rolling recensus by trained inter-
viewers. Verbal autopsies (VAs) were conducted by 
medical assistants at a median of 1 month (range: 2 weeks 
to 20 months) following death, using a modified version 
of the WHO 2012 tool.27 All data underwent double 
entry into a Microsoft Access database and conflicts were 
flagged for cleaning.
Vaccine impact analysis
Impact in Study 1 was estimated ecologically using nega-
tive binomial regression of study area- wide annual trend 
in non- traumatic 14–51- week infant mortality pre- PCV13 
and post- PCV13 introduction, adjusted for year to account 
for underlying downward trends in infant mortality and 
RV1 introduction. The annual trend was derived using 
locally weighted 12- month moving averaging as follows:
 
Yˆt = 124
(
Yt+6 + Yt−6
)
+ 112(
Yt + Yt+1 + Yt−1 + Yt+2 + Yt−2 + Yt+3 + Yt−3 + Yt+4 + Yt−4 + Yt+5 + Yt−5
)
 
where  ˆYt   and  Yt  are the trend estimate and the observed 
incidence at month t.
Additionally, we used a change- point model with the full 
time series to determine whether PCV13 and RV1 introduc-
tion occurred before significant trend changes in infant 
mortality. In change- point analysis an intervention time 
point is not prespecified, therefore, with fewer assumptions 
than interrupted time series analysis it assesses whether: 
(1) changes in incidence have occurred; (2) identifies the 
most likely time for the change point.28 We used the Stata—
bayesmh—function to fit a negative binomial Bayesian model 
for the above specified locally weighted 12- month moving 
Key questions
What do the new findings imply?
 ► PCV13 introduction, as part of a well- established EPI programme 
in a low- income, high- burden setting alongside RV introduction, is 
associated with significant reductions in infant mortality.
 ► This strengthens the growing evidence that investment in PCV and 
RV scale- up to prevent infant deaths should be prioritised.
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averaging annual trend. We used uninformative prior for 
the mean and a uniform prior for month (all values are 
equally likely), 50 000 MCMC iterations with 10 000 burn- in 
period and specified one change point. The resulting 
change point (month), pre and post change- point mean, 
mean ratio and the corresponding 95% credible intervals 
were calculated.
Postintroduction impact was ecologically estimated 
using negative binomial regression of study area- wide 
mortality versus monthly three- dose PCV13 population 
coverage, adjusted for year. Coverage was calculated as 
the cumulative number of infants who received three- 
doses of PCV13, divided by the cumulative total number 
of age- eligible infants residing in the study area and 
surviving to 14 weeks. Small population size precluded 
individual VE analysis.
Study 2
Study 2 was conducted in Mchinji, a rural district with 
a population of 465 000 in 1832 villages, based on a 
census we conducted in March 2012. Healthcare was 
provided at 1 government hospital, 11 health centres, 
354 community healthcare workers and 4 rural hospi-
tals with limited inpatient facilities that provide care for 
a small fee. Cohort recruitment ran from 24 November 
2011 (soon after PCV introduction) to 1 June 2015, and 
follow- up with mortality surveillance ran from 1 March 
2012 (before RV introduction) to 1 June 2016. This site 
does not contribute any pre- PCV13 data, precluding a 
pre–post impact analysis.
Data collection
Pregnancies, pregnancy outcome and deaths in under 5 
year olds were recorded monthly by 1059 volunteers. Field 
enumerators conducted household visits at 4 months and 
1 year of age to collect vaccine status, socioeconomic vari-
ables and verify survivorship. Under- five deaths had a VA 
conducted at median 14 months (range: 2–50 months) 
following death using the WHO 2012 tool, with vaccine 
status recorded by senior monitoring and evaluation 
officers.27 Data were single entered into a Microsoft Access 
database with in- built validation rules and underwent auto-
mated monthly cleaning; errors in identification were sent 
for field verification. A random subset of 4- month and 
1- year interviews were redone quarterly and all vaccine 
clinics were visited to audit documentation for quality 
control.
Sample size
The sample size for individual VE was calculated for 
80% power to detect a 25% reduction in non- traumatic 
infant mortality, assuming 14–51- week infant mortality of 
15/1000 live births, 80% three- dose vaccine coverage and 
15% loss to follow- up. A sample of 45 520 births surviving 
to 14 weeks and 552 death events were required.
Vaccine impact analysis
In the absence of pre- PCV13 data, population- 
level impact in Study 2 was estimated using negative 
binomial regression of yearly mortality versus yearly 
vaccine coverage, by geographical cluster, adjusted for 
two- dose RV1 coverage. Coverage was calculated as the 
number of dose- eligible infants who received one, two 
or three doses of PCV13 by 52 weeks of age, divided by 
the total number of infants residing in the cluster and 
surviving to 14 weeks. Geographical clusters were 354 
government- defined community healthcare worker 
catchment areas, with a median population of 1300 
people (IQR: 984–1687).
PCV13 VE analysis
Unadjusted and adjusted individual- level VE of three 
versus zero dose PCV13 receipt against non- traumatic 
mortality in infants aged 14–51 weeks was estimated 
using Cox regression as the primary analysis.29 30 VE was 
derived as:
 (1−HR)× 100. 
PCV13 doses received were modelled as time- dependent 
covariates, using date of vaccination recorded from 
caregiver- held health records (health passports) to split 
survival time into vaccinated and unvaccinated periods. 
Missing vaccination dates were imputed using chained 
equations with 10 imputations; all variables included in 
the primary model were used in the imputation (online 
supplementary eMethods 1). Infants who migrated did 
not contribute any survival time as vaccine status could 
not be determined.31 The proportional hazards assump-
tion was tested using Schöenfeld’s residuals.
Decided a priori, analyses were adjusted for a range of 
potential confounding factors associated with both risk of 
mortality and vaccine uptake. These included maternal 
survival, education, age and marital status, household 
assets, household construction, water and sanitation facil-
ities and a binary indicator of RV1 introduction. Individual 
RV1 and other EPI vaccine receipt (including Haemoph-
ilus influenzae B vaccine) were not included due to collin-
earity with PCV13 receipt, and too few children exclusively 
received PCV13 to conduct a subanalysis with this group. 
Distance to the nearest health facility (in kilometres) and 
season (rainy/dry) were investigated post hoc as possible 
proxies of vaccine access; however, neither showed any 
association with vaccine uptake, or survival, and were not 
included in the final model.
The following sensitivity analyses were conducted: 
Royston- Parmar flexible parametric survival models to 
describe time- varying vaccine effects32; using acute respi-
ratory infection (including pneumonia), meningitis 
and sepsis- associated mortality and diarrhoea- related 
mortality as the outcome (with children who died of 
other causes excluded from the model); using indi-
viduals who survived to 6 and 26 weeks as the eligible 
population30; random effects models to account for 
cluster- level effects. Analyses were conducted using Stata 
SE V.14.
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Definitions
Exposure
We recorded receipt of zero, one, two and three doses of 
PCV13, with three versus zero doses as the primary expo-
sure of interest. Vaccine date and receipt were collected 
during interviews and VAs from health passports, or 
caregiver recall if a written record was unavailable (online 
supplementary eMethods 2).
Primary outcome
We recorded deaths among three- dose eligible infants (ie, 
aged between 14 and 51 completed weeks) from a non- 
traumatic cause, as defined by the WHO 2012 VA guide-
lines (online supplementary eMethods 3). This primary 
outcome, although aetiologically non- specific has the 
advantage of being free from limitations in cause of 
death classification using VAs.33 Cause- specific mortality 
was included as a sensitivity analysis, using InterVA-4, a 
probabilistic Bayesian algorithm, to automate the anal-
ysis of the VAs and assign probability weighted cause of 
death.34 Overall, InterVA has been found to have reason-
able agreement (concordance coefficient=0.81) with 
physician coded cause of death in infants, but was lower 
for acute respiratory infections in similar settings.35
Patient and public involvement
Prior to the start of the study, the protocol was presented 
to the District Executive Committee and District Health 
Management teams in Mchinji and Karonga districts for 
input and approval. Extensive community engagement 
was conducted for this new data collection activity in 
Mchinji district, including the recruitment of village- level 
volunteers and meetings with traditional leaders and 
area development committees. Community consent was 
sought during study introduction.
Ethics
Verbal informed consent was obtained for all interviews. 
The study was approved by the National Health Sciences 
Research Ethics Committee in Malawi [#837], London 
School of Hygiene and Tropical Medicine [#6047] and 
Centres for Disease Control and Prevention [#6268].
RESULTS
Study 1
Prior to PCV13 introduction, between 1 January 2004 and 
30 September 2011, 10 593 live births were recorded, with 
9759 confirmed survivors at 1 year and 171 non- traumatic 
infant deaths between 14 and 51 completed weeks of age 
(mortality of 17/1000 live births). Post- PCV13 introduc-
tion, between 1 October 2011 and 1 July 2019, 9698 live 
births were recorded, with 8780 confirmed survivors at 
1 year and 45 non- traumatic deaths between 14 and 51 
completed weeks of age (mortality of 5/1000 live births, 
online supplementary eFigure 2.1). Median age at death 
was 31 weeks.
Health passports were seen in 67% of deceased and 
92% of surviving infants. Postintroduction, overall three- 
dose PCV13 coverage was 46% and 94%, and two- dose 
RV1 coverage was 65% and 92% in age- eligible deceased 
and surviving infants, respectively. PCV13 doses were 
administered at a median of 8 (IQR: 7–10), 14 (IQR: 
12–17) and 19 (IQR: 16–24) weeks.
Smoothed annual incidence data showed evidence of 
overdispersion. Pre–post negative binomial regression, 
adjusted for year, demonstrated a 28.6% (95% CI: 15.3 
to 39.8; p value<0.001) reduction in non- traumatic infant 
mortality among age- eligible infants (figure 1A). A single 
change point in the trend of infant mortality was identi-
fied in November 2012 (credible Bayesian interval: June 
2012 to June 2013). The pre change- point mean mortality 
was 19.04 (95% CI: 15.46 to 23.80), compared with a post 
change- point mean of 5.24 (95% CI: 4.12 to 6.73); the 
ratio of pre to post change- point mean was 3.69 (95% CI: 
2.64 to 4.97; online supplementary eFigure 2.2).
Adjusted negative binomial regression of monthly 
mortality against three- dose coverage found every 1 
percentage point increase in coverage was associated 
with a 2.0% (95% CI: 1.5 to 2.4; p value<0.001) decrease 
in mortality (figure 2).
Figure 1 PCV13 and RV1 vaccine coverage and age- 
eligible infant deaths during the cohort period. (A) Study 1; 
(B) Study 2. Smoother in panel A: Smoother in panel B was 
done using locally weighted regression function, with a 0.15 
bandwidth, due to the smaller number of time points. PCV, 
pneumococcal conjugate vaccine; RV, rotavirus vaccine.
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Study 2
Between 24 November 2011 and 1 June 2015, we regis-
tered 50 731 live births; 454 infants died between 14 and 
51 weeks of age and 37 926 were confirmed survivors at 1 
year (figure 3). The crude birth rate was 32/1000 popu-
lation and median age at death was 32 weeks. During the 
same period, stillbirth rates (23 and 24/1000 births in 
2013 and 2015, respectively), and neonatal mortality rates 
(26 and 27/1000 live births in 2013 and 2015) remained 
stable. Additional descriptive parameters are presented 
in online supplementary eTable 1.1.
Health passports were seen in 89% of infants, with 
higher availability in surviving than deceased infants 
(90% vs 26%)—there was no difference in PCV13 
coverage recorded between those with and without health 
passports in deceased infants (online supplementary 
eTable 1.2). A date of vaccination was available for 89% 
of children, with PCV13 doses administered at a median 
of 8 (IQR: 6–10), 14 (IQR: 11–16) and 20 (IQR: 16–22) 
weeks. Three- dose PCV13 coverage was 89% in surviving 
and 73% in deceased children (table 1); overall two- dose 
RV1 coverage was 73%. Following RV1 introduction 15 
(<0.1%) children received RV1 but no PCV13, and 757 
(3%) children received PCV13 without RV1. Between 
years 1 and 3 post- PCV introduction, non- traumatic age- 
eligible infant mortality decreased from 17 to 10/1000 
live births (figure 1B).
Across 354 geographical clusters, three- dose PCV13 
coverage ranged from 58% to 100% and mortality ranged 
from 0 to 87/1000 live births. Cluster- level impact anal-
ysis, using negative binomial regression adjusted for RV1 
coverage, found that every 1% absolute increase in three- 
dose coverage by geographical cluster was associated with 
a 1.3% reduction in non- traumatic infant mortality (95% 
CI: 0.3% to 2.4%; p value=0.02).
Adjusted Cox analysis, with time- dependent PCV13, 
estimated three- dose PCV13 VE to be 44.6% (95% CI: 
23.0% to 59.1%) against non- traumatic age- eligible 
infant mortality (table 2, figure 4). Three- dose VE was 
48.3% (95% CI: −5.9% to 74.1%) in InterVA- coded acute 
respiratory infection, meningitis and sepsis- associated 
mortality. Proportional hazards assumptions were not 
violated in either model (p value=0.63 and p value=0.10, 
respectively). When adjusted for RV1 introduction, three- 
dose PCV13 was not significantly associated with a reduc-
tion in diarrhoea- related mortality (VE: 18.5%; 95% CI: 
−57.7% to 57.8%).
Sensitivity analyses examined mortality by vaccine 
receipt from 6 weeks (one- dose eligibility) and 26- week 
survival (allowing for late dose- three receipt), giving a 
VE of 54.5% (95% CI: 48.8% to 66.1%) and 27.0% (95% 
CI: −15.8% to 54.0%), respectively. Proportional hazards 
were violated in the 6- week model but not the 26- week 
model (p value=0.003 and p value=0.58, respectively). 
Adjusting for individual and cluster- level random effects 
did not materially change the VE estimates, and these 
models were not statistically supported (online supple-
mentary eTable 2.1). Royston- Parmar analysis, allowing 
for time- varying vaccine effects, demonstrated that the 
hazard rate varied over survival time (online supplemen-
tary eFigure 3).
DISCUSSION
In two prospective population- based, geographically 
independent cohort studies in Malawi, declines in vaccine 
age- eligible infant mortality were observed following the 
Figure 2 Smoothed trend in ACM against three- dose 
PCV13 coverage from Study 1. LOWESS smoothing 
bandwidth = 0.4. ACM, all- cause non- traumatic infant 
mortality; PCV, pneumococcal conjugate vaccine; LOWESS, 
Locally weighted smoothing.
Figure 3 Cohort recruitment flow diagram for Study 2.
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introduction of PCV13 and then RV1 into the Malawi EPI 
programme (figure 1). In both settings, these declines in 
infant mortality were associated with three- dose PCV13 
coverage. In Northern Malawi, the effect has been 
sustained for nearly 8 years postintroduction. A change- 
point analysis identified a break point in the mortality 
trend in November 2012, a year after PCV13 introduction 
and shortly after RV1 introduction, supporting a vaccine- 
associated impact.
Table 1 Description of Study 2 cohort, including vaccine 
and socioeconomic status by survival
Variable
Survived
N (%)
Deceased
N (%)
Total 37 926 454
PCV13 doses*
  0 doses 1657 (4) 43 (9)
  1 dose 343 (1) 21 (5)
  2 doses 1242 (3) 53 (12)
  3 doses 33 703 (89) 331 (73)
  Missing 982 (3) 6 (1)
RV1 introduction*
  Pre- RV1 9208 (24) 131 (29)
  Post- RV1 28 718 (76) 323 (71)
Mother’s marital status*
  Married 34 055 (90) 345 (76)
  Single 2023 (5) 46 (10)
  Separated/widow 1752 (5) 47 (10)
  Mother deceased 28 (0) 10 (2)
  Missing 68 (0) 6 (1)
Mother’s education *
  None 4457 (12) 69 (15)
  Primary 28 765 (76) 339 (75)
  Secondary/tertiary 4631 (12) 39 (9)
  Missing 73 (0) 7 (1)
House quality* †
  Worst 28 920 (76) 365 (80)
  Middle 5637 (15) 51 (11)
  Best 3305 (9) 32 (7)
  Missing 64 (0) 6 (1)
Water source*
  Open source 7399 (20) 110 (24)
  Protected source 30 476 (80) 338 (75)
  Missing 51 (0) 6 (1)
Toilet facility*
  None 7334 (19) 73 (16)
  Some 30 539 (81) 375 (83)
  Missing 53 (0) 6 (1)
 
Median
(IQR)
Median
(IQR)
Household assets*‡ 1 (0–3) 1 (0–2)
Mother’s age at child’s 
birth*§
25 (21–31) 26 (22–33)
*P value<0.05 from χ2 test in categorical variables and t- test 
comparison of means in continuous variables between surviving 
and deceased children.
†House quality is a composite of the construction materials 
used to make the roof, walls and floor.
‡Household assets include: bicycle, radio, ox cart and mobile 
phone; mean in survived=1.5, mean in deceased=1.2.
§Mean in survived=26.1; mean in deceased=28.0.
PCV, pneumococcal conjugate vaccine; RV, rotavirus vaccine.
Table 2 Adjusted Cox proportional hazards survival 
analysis of non- traumatic deaths in age- eligible infants 
(Study 2)
Variable
Adjusted 
HR* 95% CI P value
PCV13 status
  0 doses 1.00
  1 dose 0.49 0.28 to 0.84 0.009
  2 doses 0.65 0.44 to 0.96 0.029
  3 doses 0.55 0.40 to 0.77 <0.001
RV1 introduction
  Pre- RV1 1.00     
  Post- RV1 0.78 0.63 to 0.97 0.023
House†
  Worst 1.00     
  Medium 0.74 0.54 to 1.02 0.063
  Best 1.00 0.68 to 1.47 0.992
Mother’s marital status
  Married 1.00     
  Single 2.33 1.67 to 3.23 <0.001
  Separated/widowed 2.30 1.67 to 3.17 <0.001
  Mother deceased 40.22 20.42 to 79.21 <0.001
Mother’s education
  None 1.00     
  Primary 1.01 0.76 to 1.33 0.964
  Secondary/tertiary 0.73 0.47 to 1.13 0.157
Water
  Protected source 1.00     
  Open source 1.24 0.99 to 1.55 0.061
Toilet
  None 1.00     
  Some facility 1.42 1.09 to 1.83 0.008
Household assets‡ 0.82 0.74 to 0.90 <0.001
Mother’s age at birth 1.04 1.03 to 1.06 <0.001
Model satisfied proportional hazards assumption across all 10 
imputations (average p value=0.629).
*All variables were included in the adjusted model.
†House quality is a composite of the construction materials 
used to make the roof, walls and floor.
‡Household assets include bicycle, radio, ox cart and mobile 
phone.
PCV, pneumococcal conjugate; RV, rotavirus vaccine.
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Measuring the effect of a new vaccine at the popula-
tion level can be challenging, particularly in resource- 
limited settings and where background child mortality 
is changing rapidly.36 We studied two populations using 
different methods at scale, allowing for the measure-
ment of plausible change and validation of our find-
ings between studies. The communities participating in 
these studies were typical of many in rural Africa, with 
well- functioning EPI programmes but a high prevalence 
of undernutrition, HIV, malaria and resource- limited 
health systems. Our study sites had comparable birth and 
under 5- year- olds mortality rates to reported Malawian 
national averages pre- PCV13,37 suggesting our birth and 
death ascertainment had adequate population coverage. 
These two settings and their consistent results support 
the generalisability of our findings to other contexts in 
rural sub- Saharan Africa.
The VE estimate we observed was considerably higher 
than the 25% we anticipated and may reflect the true 
impact. It is plausible that a synergistic benefit from RV1 
and PCV13 occurred that we could not account for in 
analysis. We were unable to directly adjust for individual- 
level RV1 receipt in this study, as children rarely received 
one vaccine but not the other, and therefore were not 
able to completely disentangle the effects.
It has been shown that pneumococcal pneumonia 
increases a child’s vulnerability to other infectious 
diseases,38 39 and that pneumonia often has multiple 
causative pathogens.40 41 Thus, reducing the incidence 
of pneumococcal infections likely impacts morbidity 
and mortality from common infections, such as malaria 
or viral respiratory infections, especially in the context 
of widespread undernutrition or anaemia. Indeed, our 
sensitivity analysis found only a slightly higher VE against 
suspected acute respiratory infections, meningitis and 
sepsis, than against all- cause mortality. Although, it is 
important to note that the delay between deaths and 
VA may have resulted in recall bias for specific symp-
toms, such as cough or difficulty breathing. In this 
context, planned evaluation of combined or sequential 
introduction of childhood vaccinations needs to carefully 
consider whether evidence of individual vaccine impact 
and effectiveness can be ascertained. Further program-
matic investigation of the potential for additive bene-
fits of these vaccines, in the context of on- going public 
health initiatives to reduce under 5- year- olds mortality is 
needed to optimise scale- up.
The impact estimate based on the pre–post analysis, 
accounting for background trends in infant mortality 
and RV1 introduction, is consistent with the finding 
from the 9- valent PCV trial in The Gambia,42 and RV1 
introduction in low- income and middle- income coun-
tries.20–22 High vaccine coverage was rapidly achieved 
and prevaccine data have indicated the importance of 
infant mortality from respiratory and diarrhoeal disease 
in Malawi.1 36 43 A reduction in vaccine- type invasive pneu-
mococcal disease following PCV13 introduction in Malawi 
has been reported from southern Malawi.44 45 Addition-
ally, a concurrent study in central Malawi observed a 36% 
reduction in inpatient pneumonia mortality, and a 47% 
reduction in hypoxemic pneumonia.45 These simulta-
neous reductions in more specific pneumococcal and 
clinical endpoints add support to the finding that PCV13 
was associated with a reduction in population- level non- 
traumatic infant mortality. A 64% reduction in hospital-
ised rotavirus diarrhoea has also been reported following 
RV1 introduction in Malawi.19 Thus given what is known 
about the individual effectiveness of these vaccines on 
disease- specific endpoints, an interaction between them 
would not have to be large to deliver major synergistic 
public health benefits.
Our data suggest that three- dose PCV13 receipt was 
more effective in younger infants. The sensitivity anal-
ysis of infants surviving to 26 weeks, by which time the 
majority of children had received all three- doses, found 
a lower and non- significant VE. The Royston- Parmar 
models, allowing VE to vary over survival time, supports 
the finding of differing effectiveness by age.32 However, 
this may be explained by epidemiological factors (eg, 
survivorship bias). Survivorship bias may also contribute 
to the apparent lack of a dose- response which we 
observed, as those surviving to three- dose eligibility are 
more robust than those who only survived long enough 
for one or two doses. As pneumonia- related deaths were 
concentrated in younger infants, programmatic emphasis 
on vaccination timeliness may optimise VE,7 46 although a 
recent modelling exercise found minimal impacts of PCV 
delays on mortality.47
As a large and complex observational field study, 
there may be residual confounding biassing our VE esti-
mate. Although we adjusted for key sociodemographic 
confounders, it is unlikely we captured them all. We were 
also unable to adjust for individual exposure to concur-
rent community- based public health interventions which 
were on- going in both sites. Systematic monitoring of 
health systems performance and key child health indi-
cators was not feasible, but should be recommended 
for future studies. In Study 2, a mentorship programme 
Figure 4 Kaplan- Meier survival curve (Study 2).
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for paediatric pneumonia diagnosis, management and 
the introduction of pulse oximetry was implemented.48 
If parents of vaccinated infants were more likely to 
seek healthcare, then vaccinated infants may have also 
received improved pneumonia case management. This 
would both reduce mortality in the vaccinated and 
magnify any underlying frailty bias (ie, if unvaccinated 
infants do not seek improved care), increasing apparent 
VE. However, random effects models that accounted for 
unmeasured cluster- level confounding did not change the 
VE estimates and were not statistically supported (online 
supplementary eTable 2.1). Nevertheless, the argument 
that children unable to access vaccines also lack access to 
treatment interventions only strengthens the argument 
for vaccine introduction and maximisation of population 
coverage, particularly among the most vulnerable.
Under- ascertainment of unvaccinated survivors, vacci-
nated non- survivors or misclassifying surviving unvac-
cinated infants as vaccinated could all increase the VE. 
Incomplete follow- up was higher in surviving infants, and 
if these lost infants were more likely to be unvaccinated 
(eg, children of migrant farm labourers with limited 
access to care) it would increase apparent VE by reducing 
unvaccinated survival time in the analysis. We were unable 
to assess differences between those who did and did not 
complete follow- up, although crude birth, mortality and 
vaccination rates were comparable to national estimates.
We recorded more health passports in surviving than 
deceased infants. It is common practice in Malawi to 
bury health passports when a child dies, leading to lower 
documentation of vaccine status from these children. 
Reliability of caregiver recall is varied and may be subject 
to recall and social desirability bias,49–51 the direction of 
which is unknown in our population. Relying solely on 
health passports would also have introduced bias, as it 
may be associated with higher healthcare engagement 
and vaccination. We conducted several quality assur-
ance activities around vaccine status to mitigate these 
biases where possible and have previously published 
our decision process for including caregiver recall 
data.30 We compared vaccine status in deceased infants 
between those with and without a health passport and 
found similar rates (online supplementary eTable 1.2), 
suggesting that these biases are unlikely to have substan-
tially influenced our VE estimate.
The mortality impacts we observed are likely attribut-
able to more than prevention of severe life- threatening 
pneumococcal infections and severe rotaviral diar-
rhoea, and should be interpreted in the context of 
an existing functioning EPI programme, concurrent 
public health interventions and longer- term downward 
trends in infant mortality. Nonetheless, our results 
show significant declines in infant mortality in Malawi 
following sequential PCV13 and RV1 introduction, with 
adjustment for background trends. Considering prior 
trial evidence of efficacy for these vaccines against 
infant mortality, and the sustained impact over time, 
these findings support the continued investment in 
introduction and scale- up of these vaccines that target 
pneumonia and diarrhoea, particularly in high child 
mortality settings.
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